An observational study in SSc-Systemic Sclerosis, sponsored by University of Patras. Recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by University of Patras · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Scleroderma, Systemic with a site in Greece — 4 open to participants now, 5 under way, 3 of them phase 3. Scleroderma, Systemic · Greece.
Among the 12 studies in Scleroderma, Systemic with a site in Greece, this one is the only one that started in 2025, is one of 2 observational ones, and was the 10th registered.
614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.
Browse Scleroderma, Systemic studies →4 of the 12 studies in Scleroderma, Systemic with a site in Greece are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Greece, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in Greece, United States, Argentina and 42 more countries
Ages 18+
GlaxoSmithKline · Sites in Greece, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 5
First in 2011; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 100 across 145 observational studies indexed under Scleroderma, Systemic.
Median enrollment 213 across the 10 interventional studies, 333 across the 2 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
University of Patras is the lead sponsor of 70 studies on the registry; 10 are open to participants now.
University of Patras has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
1 of the studies in Scleroderma, Systemic with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Scleroderma, Systemic with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment
Systemic sclerosis (scleroderma) is a rare systemic autoimmune disease. It primarily affects the skin, but it can also involve other vital organs and systems, and is characterized by fibrosis, vascular abnormalities, and the production of autoantibodies. Its main pathological feature is the excessive production and deposition of collagen in the skin and other organs.
Mortality in scleroderma varies depending on the type and severity of the disease, particularly on whether vital organs are involved. Patients with limited cutaneous scleroderma generally have a better prognosis and life expectancy, whereas those with diffuse scleroderma face a higher risk of death from disease-related complications, mainly due to lung involvement.
Pulmonary involvement in scleroderma is common, either affecting the pulmonary blood vessels (pulmonary hypertension) or the supporting structure (interstitium) of the lungs, leading to interstitial fibrosis.
Objective:
The aim of the study is to compare patients receiving only dual immunosuppressive therapy (control group) with patients receiving dual immunosuppressive therapy combined with antifibrotic treatment (e.g., nintedanib).
Methods:
This will be a retrospective study including patients with scleroderma and diffuse pulmonary fibrosis who are followed at the Rheumatology Department of the University General Hospital of Patras and are receiving the two proposed treatment regimens. Because fibrosis and its progression are slow processes, we propose a comparative analysis of outcomes in both groups at 2 years from treatment initiation.
Inclusion criteria:
Presence of pulmonary fibrosis (documented by chest HRCT), regardless of whether pulmonary function tests show a restrictive pattern or not.
Availability of pulmonary function tests for each patient at the following time points:
0 months (baseline) 6 months 12 months Patients (controls) should be receiving either dual therapy (MMF + RTX) or triple therapy (MMF + RTX + nintedanib).
Analysis:
Statistical analysis will be performed using the unpaired two-tailed Student's t-test.
Expected results / originality / contribution to science:
To date, no similar study exists in the international literature. Since interstitial lung disease is the leading cause of death in patients with scleroderma, the results of this study may contribute to improved management. We hypothesize that the combination of dual immunosuppressive therapy and antifibrotic treatment will be superior to dual immunosuppressive therapy alone.
Patients with ssc-ild
Inclusion Criteria:ild-ssc with double
-
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Comparison of the two groups
Drug: Antifibrotic drugs (nidanib or pirfenidone) · Drug: MMF Immunosuppression
Patients with rituximab and mmf
Drug: MMF Immunosuppression
Ssc - ild
we will compare patients with SSc-ILD taking RTX and mmf and patients that are taking RTX,mmf and nintedanib
Also known as: RITUXIMAB
pulmonary function test
For outcome number 1: FVC as a percentage compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed between baseline and each subsequent value at each prespecified time point. For outcome number 2: FEV1 as a percentage compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed between baseline and each subsequent value obtained at each prespecified time point. For outcome number 3: FEV1/FVC (ratio) compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed between baseline and each subsequent value obtained at each prespecified time point. For outcome number 4: TLCO (corrected for Ht) as a percentage compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed as described above.
Time frame: From enrollment till the end of study -1 years later
Started Jun 2025 (actual). Primary completion is estimated for Jul 2026, 13 months after the start.
Of 59 non-industry observational studies under Scleroderma, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 80. This study's planned 13 months is below that.
Counting every sponsor, half of 61 studies reached it within 44 months; a quarter within 17 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Patras